COMPANY PRESENTATIONUPDATE 9M21

SIDO IJ | SIDO JK

This presentation was prepared solely and exclusively for discussion purposes. Thispresentation and/or any part there of may not be reproduced, disclosed or used without theprior written consent of PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK (SIDOor the Company).

This presentation, as well as discussions arising there from, may contain statementsrelating to future expectations and/or projections of the Company by its management team,with respect to the Company. These statements are generally identified by forward-lookingwords such as “believe”, “expect”, “may”, “will”, “plan”, “estimate”, “anticipate”, or othersimilar words. These statements are presented on the basis of current assumptions whichthe company’s management team believes to be reasonable and presumed correct basedon available data at the time these were made, based on assumptions regarding theCompany’s present and future business strategies, and subject to certain factors whichmay cause some or all of the assumptions not to occur or cause actual results to divergesignificantly from those projected. Any and all forward looking statements made by theCompany or any persons acting on its behalf are deemed qualified in their entirety bythese cautionary statements.

This presentation is solely for informational purposes and should in no way be construedas a solicitation or an offer to buy or sell securities or related financial instruments of theCompany.

Disclaimer

2

Table of Contents

3

Introduction

Company Highlights

Business Update 9M 2021

Financial Summary

Appendix

1

2

3

4

55

INTRODUCTION

Largest herbal product manufacturer in Indonesia with leading product portfolio and strong financials

Products that cater to Indonesian consumers across all demographics (gender, age and income groups)

122 distribution pointsthroughout Indonesia

Well-established Presence

Stable dividend payout ratio averaging >90% (FY20: 100%) and debt free balance sheet

Attractive Financials

2017-20 CAGRSales : +9%NPAT : +21%

Numerous Accolades

More than 70 years of heritage

Market Cap: USD1.6bn(Listed since 2013)2020 Sales:USD 236.5mn2020 NPAT: USD 66.2mn

More than 4,000 employees

5Market data as of 30 Dec 2020, FX of 14,105 IDR/USD.

FORBES – Asia Best Under a Billion & 50 Best of the Best Companies (2020)

Various other Indonesia most valuable brand awards and recognitions in ESG

GOLD PROPER – The highest recognition from the Ministry ofEnvironment and Forestry

OP Margin: 35%NPAT Margin: 28%ROA: 24%ROE: 29%

Finance Asia –Indonesia Best Managed Listed Company & Best CEO (2021)

Established to preserve Indonesian heritage through innovation, local knowledge and passion for good

6

1940 1970 1984 1997 2000 2013 2014 2018 2019 2020

Founded by Mrs. Rakhmat Sulistio in 1940 with the first formula of Jamu Tolak Angin. In 1951, the company SIDO MUNCUL was established

PT Industri Jamu dan Farmasi Sido Muncul

was officially incorporated

Modern production facility was installed in Lingkungan Industri Kecil (Semarang, Central Java) to meet growing market demand

New 32 ha factory complex in Klepu, with facilities having CPOB, CPOTB, and various ISO standards, was inaugurated

Acquired PT Berlico Mulia Farma to expand business to pharmaceutical industry

Received Halal Certificate from Indonesian Ulama Council (MUI) and Implementation ofPolymerase ChainReaction (PCR)

Cornerstone-laying was held for the construction of a new,

bigger, and modern factory complex in Klepu, Central Java

Conducted Initial Public Offering with issue price

of Rp580 per share.Ticker code: SIDO

• Completed construction of a new, integrated herbal

liquid production facility, with capacity of up to 180mn

sachets/month.• First shipment to the Philippine

• Received GOLD PROPER award from Indonesia ministry of environment and forestry.

• Completion of RTD production facility.

Comprehensive range of products with strong brand equity and awareness among Indonesian consumers

7

Herbal & Supplement Food & Beverages Pharmaceutical

More than 300 SKUs

Scientific and Consumer Driven Innovation

• Modernized “JAMU”, using a wide range of natural Indonesian herbs and medicinal plants, with proven and long history of efficacies

• Herbal-based supplements to meet the modern lifestyle of Indonesian consumers

64% OF REVENUE

• Pioneer of fruity flavor energy drink in Indonesia, not just an energy booster but also a refreshing drink

• Wide variety of herbal-based drinks and confectioneries. Some with health maintenance benefits

32% OF REVENUE

• Various over-the-counter drugs and consumer health products (~60% contribution), and prescription drugs (~40% contribution)

4% OF REVENUE

Experienced management team with proven track records in business and the industry

Board of Commissioners

President CommissionerJonatha SofjanHidajat

>40 years experience in herbal business

CommissionerJohan Hidayat

>40 years experience in herbal business

CommissionerSigit Hartojo Hadi Santoso

>40 years experience in herbal business

CommissionerYoung Taeg Park

>35 years experience in financial industry, now serves as Chairman and Managing Partner Affinity Equity Partners

CommissionerEric Marnandus

>20 years experience in financial and consulting companies, now serves as Executive Director at Affinity Equity Partners Indonesia

Independent CommissionerProf. Lindawati Gani

>30 years experience in finance accounting & audit. Also, serves as committee audit in several Indonesia plc

Independent CommissionerDr. M. AdibKhumaidi SpOT

>20 years as doctor and Orthopedics Traumatology Specialist

Independent CommissionerSegara Utama

>45 years experience in financial industry. Also, serves as commissioner in several companies

Board of Directors

President DirectorDavid Hidayat

>35 years experience in herbal business, expertise in operational

DirectorIrwan Hidayat

>40 years experience in herbal business, expertise in marketing

DirectorLeonard

>20 years experience in finance, audit, taxation and IT at several reputable companies

DirectorDarmadji Sidik

>20 years experience in sales and logistics at a reputable consumer company

COMPANY HIGHLIGHT

Commitment to continuously deliver value to all stakeholders

Fully-integrated and high quality supply chain, including best-in-class production facility with pharmaceutical grade certification and advanced technologies

Key company highlights

10

Leading player in the fast growing Indonesia consumer health market1

Continuous product and business innovation2

Track record of successful and systematic market penetration3

4

5

38.3%

16.7%12.8% 13.5%

4.0%

SIDO A B C D

10.3% 9.3% 8.9% 8.3%

4.9%

HerbalProducts

Vitamins andSupplements

OTC SportsNutrition

WeightManagement

Leading player in the fast growing Indonesian consumer health market and #1 player in herbal segment

11

1

Pre-cold is the most consumed category in herbal segmentD Market leader in herbal cold

symptoms product categoryFIconic brands synonymous with herbal consumer health in Indonesia

E

~72%

Others~28%

Cold Symptoms: 55%

Heatiness: 30%

Digestion: 5%

Herbal Analgesics: 5%

Others: 5%

Cultural preference for herbal-based and natural products

Prevalent light digestive and respiratory ailments due to climatic and micro-climatic conditions

Compelling demographic and cultural driversA SIDO is the market leader in the

“JAMU” industry.*CHerbal has the fastest growth within consumer health segmentB

CAGR 2019-14

Source: Nielsen (2020) & Company Research.* Total Sales Volume of Jamu Industry—Nielsen FY 2020.

12

Sido Muncul has demonstrated the industry-leading capabilities in herbal medicine, through coordinated multi-pronged strategy ensuring sustainable long-term growth

First herbal producer to modernize the production of herbal medicines, creating a major, standardized brand

Innovative and convenient liquid single-use sachet accelerated market penetration, while also introducing other forms to expand consumer base

Formulation Innovation

Reformulating Tolak Angin forms to efficiently attract and target younger generation customers

Significant focus on improving customer experience and perception of taste for herbal medicine

Tolak Angin is consumed by customers across all demographics

Improving the Customer Experience

Strong relationship with local distributors nationwide – easily accessible even at local mom and pop stores, as well as modern channels

Rapid penetration into global markets, including the Philippine and Nigeria

Extensive Network Creating Access

Successful 2015 marketing campaign educated consumers on using product as preventive measure vs. instant relief, boosting consumption frequency

Use of catchy taglines with elite celebrities also increased the frequency of product consumption

Innovative and Proven Marketing

The first herbal player to obtain BPOM* standardized certification– Enables product to be distributed

nationally, and enter modern trade Among few herbal medicines to receive

‘scientifically proven’ certification Owns full IP rights since 2018, with

improved gross margin

Quality and Certifications

* National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan).

Tolak Angin is the #1 herbal product in Indonesia1

13

Kuku Bima Ener-G! is the pioneer of fruit flavored energy drink in Indonesia 1

Going against the industry norm of energy drink formulation, taste and color, Kuku Bima Ener-G! revolutionized the category by “thinking outside the box”

Innovative Iconic Future

From Jamu product extended to energy drink category

Launched in 2004, Kuku Bima Ener-G! introduced powder energy drinks with various fruit flavors and quickly became a leading player in the energy drink category in Indonesia

ROSA! is the brand tagline, which means STRONG in Javanese, and has become an iconic slogan

Most of the product’s advertisement carry Indonesia tourism theme, to introduce Indonesia culture to consumers

Top 2 energy drink player in the country with >40% market share in its category

Ready-to-Drink format offers increased convenience for younger consumer segment

Further expansion into international market, especially in Nigeria and Malaysia

14

Product portfolio expansion through continuous product innovation2

Herbal & Supplement Food & Beverages

SIDO launches 2–3 new products or variants annually

SIDO’s new product development engine is driven by strong local market insights and understanding of customers’ needs and preferences, coupled with superior R&D in herbal medicine

This has enabled us to constantly bring new innovative products to develop new market niches

Entry to the pharmaceutical industry through acquisition of PT Berlico Mulia Farma2

Expansion into the pharmaceutical sector resulted in complementary organic growth

Anacetine(medicine to reduce fever for kids)

Suprabion(blood booster multivitamin)

Berlosid(medicine for gastritis)

OBH Berlico(medicine for cough)

Licokalk(calcium multivitamin)

Minyak Telon Tiga Anak(Ointment for baby & kids)

• SIDO acquired PT Berlico Mulia Farma (“Berlico”) in 2014

• Key strategic rationale was to leverage the complementary value proposition of herbal and pharma products resulting in a wider portfolio of consumer health products

• Berlico has its indpendent manufacturing facility which produces >80 product SKUs, from OTC drugs, consumer health products (pharmaceutical supplements and topical medicines), to prescription drugs

• A distribution network covering 16 major cities in Indonesia

15

16

Track record of successful and systematic market penetration3

Targeted expansion across Java

Leverage strong understanding ofJavanese consumer tastes andpreferences

Relatable brand heritage

Establishment of extensive pan-Java distribution network, with 122 sub-distributors nationwide and access to >100,000 wholesalers & retailers and >2 million POS

East Indonesia expansion

SEA and Africa

expansion

Strong distribution network (Distribution points)

West Indonesia expansion

Focus Export Countries: Philippine, Nigeria, & Malaysia

On-the-ground presence in Philippines through branch office and subsidiary in Nigeria

Marketing support to establish the brand awareness and product knowledge

17

Best-in-class production facility with pharmaceutical-grade certification and advanced technologies4

• GMP standard for Traditional Herbal Medicine (CPOTB) and Pharmaceutical (CPOB)

• ISO 9001 for quality management system, ISO 22000 for food safety management, and ISO 17025 for laboratory management system

• Hazard Analysis & Critical Control Point (HACCP) to identify food safety risks, prevent hazards in food safety, and convey legal compliance

• Halal certification for over 200 SKU products

• Main operation is located in Klepu, Central Java, over a 32 ha land area, manufacturing all Herbal and F&B products

• Total liquid herbal production capacity of up to 180mn sachet per month, after completion of new herbal manufacturing plant in 2018. Post expansion, utilization rate for herbal production facility is still ample at around 50%

• New 1 ha raw material storage warehouse with storage capacity of 6-month inventory

• Commissioning a new RTD manufacturing plant

Semarang Herbal Indo Plant

Berlico Mulia Farma

• Main facility to extract all herbal raw materials into liquid or powder products

• New extraction facility was completed in 2017, with higher extraction yield, larger capacity and improved efficiency in raw materials usage

• Located in Yogyakarta (near Central Java)

• Manufacturer of the entire pharmaceutical product range, including solid, semi-solid, and liquid formats

• Pharmaceutical GMP standard (CPOB)

Sido Muncul Facility

Certifications

182 196 217

236

2017 2018 2019 2020

18

Strong financial profile5

Steady sales growth… …coupled by improving profitability

Resulting in best-in-class returns… …and strong cash position with no leverage

Financial performance of SIDO has exhibited consistent growth and profitability resulting in financial efficiency

EBIT NPAT

EBIT Margin NPAT Margin

2017-19 CAGR:

EBIT: +22%

NPAT: +21%

ROA ROE

1FX of 14,105 IDR/USD

CAGR: +9%

USD mn1 USD mn1

USD mn1

45 58

73 82

38 47 57 66

25%30%

33% 35%

21%24%

26% 28%

2017 2018 2019 2020

17%20%

23% 24%

18%23%

26%29%

2017 2018 2019 2020

64 57 61

73

2017 2018 2019 2020

Focus on shareholder return5

SIDO has embarked on a transformation journey to deliver shareholder value,with plenty of strategic initiatives still to be completed

19

200

300

400

500

600

700

800

900

1000

Jan-

18

Feb-

18M

ar-1

8

Apr-

18M

ay-1

8

Jun-

18Ju

l-18

Aug-

18

Sep-

18O

ct-1

8

Nov

-18

Dec-

18

Jan-

19

Feb-

19M

ar-1

9

Apr-

19M

ay-1

9

Jun-

19Ju

l-19

Aug-

19

Sep-

19O

ct-1

9

Nov

-19

Dec-

19

Jan-

20

Feb-

20M

ar-2

0

Apr-

20M

ay-2

0

Jun-

20Ju

l-20

Aug-

20

Sep-

20O

ct-2

0

Nov

-20

Dec-

20

IDR/share

Transfer of trade secret formulations to SIDO & termination of 1.5% royalty fee

First export shipment to the Philippines

Appointed David Hidayat as the new CEO along with new, professional BOD members

• Commercial production of the new liquid herbal facility in Klepu

• Received Halal Certificate

First export shipment to Nigeria under Muncul Nigeria Ltd

30th Anniversary Mudik Bersama

2019 Forbes Best of the Best Award

First Annual FY18 Sustainability Report, in accordance with GRI Standards

Indonesia 1st

large-scale social restriction (PSBB)

Indonesia 1st

COVID-19 case

First export shipment to Saudi Arabia

Stock split 1:2

Gold Proper Award

FORBES – Asia Best Under a Billion & 50

Best of the Best Companies

Indices Inclusion in IDX(Excl. JCI)

5 611

FY18 FY19 FY20

Number of Equity Shareholders

6.7k 12.2k

71.1k

FY18 FY19 FY20

ADTV (IDR bn)

3.1 3.9

12.2

FY18 FY19 FY20

BUSINESS UPDATE9M 2021

SIDO delivered stellar performance in 3Q21Highlights of financial results

21

Strong and diversified revenue growth Continued margin improvement

(IDR bn / %growth yoy)

Revenues(IDR bn / %margin)

NPAT

• Stable raw material prices

• Operational excellence

• Effective cost management

Healthy financial position

(IDR tn)

Cash Balance

• Solid balance sheet with strong cash generation

• Zero leverage

Higher dividend distribution

13 15 18

25

31

80% 81%81%

90%

100%

2016 2017 2018 2019 2020

(IDR / %payout)

Final DPS

• Increasing shareholder value

1.03 1.03

1.25

0.80 0.82

3Q20 4Q20 1Q21 2Q21 3Q21

A. Favourable consumer trend

B. Sustained growth from leading products and distribution expansion

C. Higher contribution from new products

D. Embracing digital channel

798 1,122

2,257

2,776

3Q20 3Q21 9M20 9M21

227 363

641

865

28%

32%

28%

31%

3Q20 3Q21 9M20 9M21

+41%

+23%

+60%

+35%

Indonesia has successfully weathered COVID-19 2nd wave due to the Government’s decisive and swift response

22

• Prolonged COVID-19 pandemic makes consumers more aware of their health and wellness. Surging demandfrom the market has made Healthcare and Pharmaceutical sector increased beyond other FMCG sectors.

• Declining COVID-19 cases and improving economy are helping improve consumer confidence.

• In combination, these factors will support continued strong demand for herbal supplements and multivitamins asconsumers want to maintain their immune system and healthy lifestyle.

source: Bank Indonesia, Covid19.go.id, Company Estimation

Higher vaccination penetration, record low infection rate, and loosening mobility restriction should help accelerate economicrecovery and promising growth outlook from 4Q21-onward.

Indonesia COVID-19 Cases & Vaccination Rate

Consumer Confidence Index

96

75

80

85

90

95

100

105

110

0%

5%

10%

15%

20%

-

10

20

30

40

50

60

('000) New COVID Cases Vaccination Rate

3%5%

-2%

1% 0%

10% 9%

13% 12% 11%8%

2%

40% 40%

TTM 3Q

Retail Sales Value Growth

A

• Tolak Angin sales increased more than40% yoy for 3Q21 and more than 20%for 9M21 versus 9M20.

• Campaign story that makes clearer thebenefits of Tolak Angin for immunitybrought TA sales volume to the nextlevel.

Sustained high demand for immunity-boosting supplements and distribution penetration efforts have boosted SIDO’s performance

Number of Outlet Coverage

• SIDO’s outlet coverage has reached around 131k wholesalers and retailers as of 9M21.

• Outlet coverage expansion continued,with more than 50% of new outletscontributed by East Indonesia.

• Focus of the expansion is on product availability and accessibility improvement nationwide.

• Healthy drink products continued tobook solid performance with growth of48% yoy for 9M21.

• Vitamin C drink increased more than250% yoy for 9M21 and has become#2 in MT channel based on salesvolume.

• New Susu Jahe variant: Susu JaheSuper with red ginger as the mainingredients, good for maintaininghealth.

23

80k

113k131k

2019 2020 9M21

*) Total market size of Vitamin C in Indonesia is ± IDR 4 trillion

B

24

Positive sales trend on NPD*

(IDR bn)

SUPPLEMENT27%

VIT C100066%

OTHER7%

Vit C is the top contributors of NPD*

*New Products launched in 2020-2021

• NPD has grown more than 140% qoq as of 3Q21, supportedby strong sales of Vitamin C1000 new flavour and RTDvariants, also by new supplement products (soft gel, JSH,Sambilito, etc.). NPD contributes 4% of total consolidatedsales.

• For the last 3 years, SIDO new products have grownsignificantly by 51% CAGR, without cannibalizing theexisting products as each of the new products addressesdifferent symptoms and efficacies.

8%

10%

9%

51%

F&B

HERBAL

SIDO

NEW PRODUCTS

SALES CAGR 2017-2020

The diversification strategy with new products (NPD) have generated excellent sales growth and set solid fundamental for the future

-

10

20

30

40

50

60

70

3Q20 4Q20 1Q21 2Q21 3Q21

C

SIDO has cooperated with >20 marketplaces in Indonesia Leveraging online marketplaces’ broad exposure (B2C & B2B)

Reaching out to new customers through thematic marketing campaign and promotion

Developing brand awareness and product diversification

Herbal Supplement

57%

Tolak Angin 19%

Vit-C 1000 8%

Powdered Jamu 6%

Other 11%

SIDO’s Best Selling Products

via Online

• Herbal supplement products are #1contributor of SIDO online sales.

• Diverse needs of online customershave brought opportunity for SIDO toexpand product diversity andincrease brand awareness of herbalsupplement portfolio.

25

D

26

Corporate action update:

• SIDO distributed interim dividend on Aug 27, with amount of IDR 15.30 per share or IDR 455.48 bn in full amount (90.7% payout ratio of 1H21 Net Income).

• Shareholders approved to distribute bonus shares with ratio of 131:1 from the results of EGMS on Sep 3. Around 217 mn bonus shares had been distributed on Oct 5.

Completed installation of 2 MWp Solar Panel in factory area

Corporate Update on 3Q 2021

*estimated yield of electricity generated

Solar PV Produce*2,336 MWh / Year

1,900 Tons CO2

Reduction of Carbon Emissions

27,374 Trees Seedlings Grown for

10 Years

= +

27

Efforts in sustainable initiatives implementation have been fruitful

• Sustainalytics upgraded SIDO ESG rating to LOW RISK

• The rating upgrade is based on strengthening and implementation on ESG policyand improvement on public disclosures regarding initiatives and programs alongwith the progress and achievements, increase commitment by having specifictargets, such as: emission reduction, energy & water efficiency, etc.

• SIDO received the Green Industry – level 5 award for the 4th times. GreenIndustry Level 5 is the highest awards, awarded by Ministry of IndustryIndonesia, for the company's efforts in attribute to production efficiency andenvironmentally friendly.

• Aspects of the assessment on the production process, emissions & wastetreatment, and company management got a high score with total of 91 out of100.

GREEN INDUSTRY – LEVEL 5

FINANCIALSUMMARY

Benefiting from strong demand of herbal supplement & vitamin products, SIDO continued delivering strong results up to 9M21

29

• Surging demand from domestic market boosted SIDO topline performance in 3Q21 (+41% yoy).Tolak Angin group and Healthy Drink products were the top growth contributors.

• Overall export sales increased by 39%, contributing 2.6% of total sales as of 9M21. Nigeria andMalaysia are still top export contributors as of 9M21.

• A&P cost ratio was stable at 9% of sales. Overall, OPEX ratio to sales was 18%, lower comparedto historical ratio (20%-21%) due to higher sales performance and efficient operations.

• SIDO continued to improve its margin and booked higher NPAT growth of 35% with margin of31%.

(IDR Billion – Unaudited)

18.0

24.5

31.4

12.5 15.3

81% 90% 100% 90% 91%

2018 2019 2020 Interim'20 Interim'21

DPS %Payout

200

127106

74

2019 2020 9M21

SIDO has a healthy and solid balance sheet

(IDR Billion – 2018-2020 (Au), 9M21 (Un))

Cash & Cash Equivalents

Capital Expenditure

TargetCAPEX ‘21

Dividend Per Share

30

806865

1,032

825

2018 2019 2020 9M21

+22%

CAGR 2020-2018+32%

Positive outlook for Herbal and Supplement industry as consumption has become habitual for Indonesian consumers to keep them healthy

31source: Company Research & Estimation

• Trust towards local wisdom with JAMU as the natural remedies for health support has been growingfor the past decades along with the trend of natural lifestyle. E-commerce has a big role in thedevelopment of herbal supplements market, not just as platforms to sell the products but also toprovide product education.

• Vitamins have bright outlook and huge market opportunities especially post-Pandemic, with soaringdemand for extra immune booster products from the market. Vitamin C and D are still expecting to beconsumers’ primary choice to support and maintain health.

• The positive trend of Herbal and Supplement consumption will be supported by Indonesia’s risingmiddle class and demographic bonus.

5

15

25

35

45

2018 2019 2020 2021F 2022F 2023F 2024F 2025F

Vitamin & Supplement Market Outlook

(IDR tn)

5

10

15

20

2018 2019 2020 2021F 2022F 2023F 2024F 2025F

Herbal Medicine Market Outlook

(IDR tn)

32

Optimistic future with double digit target in 2022With potentially fast economic recovery and increased focus on healthy lifestyle, SIDO is optimistic to face 2022 and aims to deliver double digit growth both for top and bottom line.

Growth guidance

2022: Sales & NPAT ~15%

Growth Guidance 2021:Sales >15% and NPAT >25%

CAPEX IDR 180 - 200 billion

Optimizing domestic

distribution and products diversification

Focus on export

recovery and expansion

Strengthening digital

presence in online

platforms and marketplaces

Maintain margin and

improve business process

Key Takeaways:

• Successfully navigated all the challenges and uncertainties in 2020 and2021 and continued delivering double digit growth.

• More experienced and agile leadership team to face the challenges upahead and execute the strategy consistently.

Additional points:

SIDO has ample production capacity from 2018’s major expansion and is ready to seize surging market demand in 2022. Total utilization rate is currently at 60%-65%.

APPENDIX

P/L Statement – 9M 2021

34

IDR Billion - Unaudited 9M21 9M20 ∆ %gr.SALES 2,776 2,257 519 23%COST OF GOODS SOLD (1,215) (1,040) (174) 17%GROSS PROFIT 1,562 1,217 345 28%

%Margin 56% 54% 2%Selling & Marketing Expenses (356) (305) (51) 17%General & Administrative Expenses (144) (134) (10) 7%Other Operational Expenses / Incomes 17 9 8 95%OPERATING PROFIT 1,079 786 292 37%

%Margin 39% 35% 4%Finance Income 31 37 (6) -18%Finance Cost (1) (0) (0) 101%PROFIT BEFORE INCOME TAX EXPENSES 1,108 823 286 35%

%Margin 40% 36% 3%Income Tax Expense - Net (243) (182) (61) 34%PROFIT FOR THE YEAR 865 641 225 35%

%Margin 31% 28% 3%

Subsidiaries to support vertical integration of operations from upstream to downstream

The commencement of operation:

1987

Business activities: Trading

The commencement of operation:

1993

Business activities: Pharmaceutical

The commencement of operation:

2018

Business activities: Trading

The commencement of operation:

2009

Business activities: Herbal Extraction

Solid operation support from subsidiaries to answer customer demands

PT HOTEL CANDI BARU (60.5%)

*PUBLIC(18.4%)

*Including 12.2mn treasury shares35

CONCORDANT INVESTMENTS(21.1%)

PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK

HEAD OFFICE:Office Sido Muncul, Lt 1 – Gedung Hotel TentremJl. Gajahmada No. 123Semarang - Indonesia

BRANCH OFFICE:Grha Muncul Mekar, fl. 8th

Jl. Panjang Arteri Kelapa Dua, No. 27Kebon JerukJakarta Barat - Indonesia

EMAIL: investor.relation@sidomuncul.co.id

WEBSITE:https://investor.sidomuncul.co.id/en/home.html